Follow us

Search News Archives
Events
«  »
SMTWTFS
 12345
6789101112
13141516171819
20212223242526
2728293031 

 


Subscibe to our YouTube channel

 

 

E-Newsletter Month  
Lab Bulletin Monthly Update July view archive
Microscopy & Image Analysis July view archive
Separation Science July view archive
Weekly Update August (3) view archive

new all Newsletter Banner

For further information or to sign up to receive any of our E-Newsletters click here


Jun 6, 2017 - The High Potent Medicines Conference

start date: Jun 6, 2017
Print
Event: The High Potent Medicines Conference
Starts: Tuesday, June 6 2017 at 09:00
Ends: Wednesday, June 7 2017 at 17:00
Location: Berlin, Germany

The manufacturing of high potent medicines has provided many challenges in terms of safe production, containment and handling due to their toxic nature. But due to changing strategies and supportive regulatory framework to protect patent infringement, pharmaceutical companies are now focusing on commercialization and development of the high potent medicines to build their pipeline of products.

While most of the highly potent drugs under development are for oncology treatments, there are also new advances in high potent compounds manufacturing particularly antibody-drug conjugates (ADC’s) which are the fastest growing segment as they deliver the cytotoxic drugs to the targeted cells.

MarketsandMarkets is proud to announce The High Potent Medicines Conference to be held on 6th-7th June 2017 in Berlin, Germany. The conference aims to focus on sharing the current market trends, technological advancements and future challenges in the high potent medicines industry where the leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations, live case studies and breakthrough panel discussions.

Key Highlights

Process validation considerations and scale-up in high potent API production

Strategies for effective management of HPAPI supply chain

Overcoming regulatory challenges for ADC’s

Validation of cleaning procedures to avoid cross contamination

Containment and safety of pharmaceutical toxic powders

Managing cleaning validation in biologics

Risk identification and mitigation for high potent compounds

Strategies to integrate PAT in the QbD process

For further information click here